Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Hypoxic cancer-associated fibroblasts increase NCBP2-AS2/HIAR to promote endothelial sprouting through enhanced VEGF signaling.

Kugeratski FG, Atkinson SJ, Neilson LJ, Lilla S, Knight JRP, Serneels J, Juin A, Ismail S, Bryant DM, Markert EK, Machesky LM, Mazzone M, Sansom OJ, Zanivan S.

Sci Signal. 2019 Feb 5;12(567). pii: eaan8247. doi: 10.1126/scisignal.aan8247.

PMID:
30723174
2.

A functional genomics screen reveals a strong synergistic effect between docetaxel and the mitotic gene DLGAP5 that is mediated by the androgen receptor.

Hewit K, Sandilands E, Martinez RS, James D, Leung HY, Bryant DM, Shanks E, Markert EK.

Cell Death Dis. 2018 Oct 19;9(11):1069. doi: 10.1038/s41419-018-1115-7.

3.

Analysis of cell proliferation and tissue remodelling uncovers a KLF4 activity score associated with poor prognosis in colorectal cancer.

Halim S, Markert EK, Vazquez A.

Br J Cancer. 2018 Oct;119(7):855-863. doi: 10.1038/s41416-018-0253-0. Epub 2018 Oct 5.

4.

ΔNp63 regulates the expression of hyaluronic acid-related genes in breast cancer cells.

Gatti V, Fierro C, Compagnone M, Giangrazi F, Markert EK, Bongiorno-Borbone L, Melino G, Peschiaroli A.

Oncogenesis. 2018 Aug 24;7(8):65. doi: 10.1038/s41389-018-0073-3.

5.

ΔNp63-mediated regulation of hyaluronic acid metabolism and signaling supports HNSCC tumorigenesis.

Compagnone M, Gatti V, Presutti D, Ruberti G, Fierro C, Markert EK, Vousden KH, Zhou H, Mauriello A, Anemone L, Bongiorno-Borbone L, Melino G, Peschiaroli A.

Proc Natl Acad Sci U S A. 2017 Dec 12;114(50):13254-13259. doi: 10.1073/pnas.1711777114. Epub 2017 Nov 21.

6.

Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer.

Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French LE, Speiser DE, Früh M, Flatz L.

Oncoimmunology. 2016 Sep 19;5(11):e1231292. doi: 10.1080/2162402X.2016.1231292. eCollection 2016.

7.

GLUT1-positive recurrent basal cell carcinoma of basosquamous subtype detected by positron emission tomography.

Hasan Ali O, Diem S, Aschwanden J, Markert E, Tasman AJ, Mueller J, Flatz L.

JAAD Case Rep. 2016 Oct 13;2(5):415-417. eCollection 2016 Sep. No abstract available.

8.

Cancer metabolism at a glance.

Vazquez A, Kamphorst JJ, Markert EK, Schug ZT, Tardito S, Gottlieb E.

J Cell Sci. 2016 Sep 15;129(18):3367-73. doi: 10.1242/jcs.181016. Review.

9.

Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer.

Ahmad I, Mui E, Galbraith L, Patel R, Tan EH, Salji M, Rust AG, Repiscak P, Hedley A, Markert E, Loveridge C, van der Weyden L, Edwards J, Sansom OJ, Adams DJ, Leung HY.

Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):8290-5. doi: 10.1073/pnas.1601571113. Epub 2016 Jun 29.

10.

The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma.

Boregowda RK, Medina DJ, Markert E, Bryan MA, Chen W, Chen S, Rabkin A, Vido MJ, Gunderson SI, Chekmareva M, Foran DJ, Lasfar A, Goydos JS, Cohen-Solal KA.

Oncotarget. 2016 May 17;7(20):29689-707. doi: 10.18632/oncotarget.8822.

11.

Mathematical models of cancer metabolism.

Markert EK, Vazquez A.

Cancer Metab. 2015 Dec 22;3:14. doi: 10.1186/s40170-015-0140-6. eCollection 2015. Review.

12.

The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7.

Stockley J, Markert E, Zhou Y, Robson CN, Elliott DJ, Lindberg J, Leung HY, Rajan P.

Sci Rep. 2015 Aug 27;5:13426. doi: 10.1038/srep13426.

13.

MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP.

Zhang X, Schulz R, Edmunds S, Krüger E, Markert E, Gaedcke J, Cormet-Boyaka E, Ghadimi M, Beissbarth T, Levine AJ, Moll UM, Dobbelstein M.

Mol Cell. 2015 Jul 16;59(2):243-57. doi: 10.1016/j.molcel.2015.05.036. Epub 2015 Jul 2.

14.

p63 controls cell migration and invasion by transcriptional regulation of MTSS1.

Giacobbe A, Compagnone M, Bongiorno-Borbone L, Antonov A, Markert EK, Zhou JH, Annicchiarico-Petruzzelli M, Melino G, Peschiaroli A.

Oncogene. 2016 Mar 24;35(12):1602-8. doi: 10.1038/onc.2015.230. Epub 2015 Jun 29.

PMID:
26119942
15.

TAp73 opposes tumor angiogenesis by promoting hypoxia-inducible factor 1α degradation.

Amelio I, Inoue S, Markert EK, Levine AJ, Knight RA, Mak TW, Melino G.

Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):226-31. doi: 10.1073/pnas.1410609111. Epub 2014 Dec 22.

16.

Transformation resistance in a premature aging disorder identifies a tumor-protective function of BRD4.

Fernandez P, Scaffidi P, Markert E, Lee JH, Rane S, Misteli T.

Cell Rep. 2014 Oct 9;9(1):248-260. doi: 10.1016/j.celrep.2014.08.069. Epub 2014 Oct 2.

17.

Sox9 mediates Notch1-induced mesenchymal features in lung adenocarcinoma.

Capaccione KM, Hong X, Morgan KM, Liu W, Bishop JM, Liu L, Markert E, Deen M, Minerowicz C, Bertino JR, Allen T, Pine SR.

Oncotarget. 2014 Jun 15;5(11):3636-50.

18.

Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling.

Weissmueller S, Manchado E, Saborowski M, Morris JP 4th, Wagenblast E, Davis CA, Moon SH, Pfister NT, Tschaharganeh DF, Kitzing T, Aust D, Markert EK, Wu J, Grimmond SM, Pilarsky C, Prives C, Biankin AV, Lowe SW.

Cell. 2014 Apr 10;157(2):382-394. doi: 10.1016/j.cell.2014.01.066.

19.

p73 regulates serine biosynthesis in cancer.

Amelio I, Markert EK, Rufini A, Antonov AV, Sayan BS, Tucci P, Agostini M, Mineo TC, Levine AJ, Melino G.

Oncogene. 2014 Oct 16;33(42):5039-46. doi: 10.1038/onc.2013.456. Epub 2013 Nov 4.

PMID:
24186203
20.

MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells.

Formosa A, Markert EK, Lena AM, Italiano D, Finazzi-Agro' E, Levine AJ, Bernardini S, Garabadgiu AV, Melino G, Candi E.

Oncogene. 2014 Oct 30;33(44):5173-82. doi: 10.1038/onc.2013.451. Epub 2013 Oct 28.

PMID:
24166498
21.

Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells.

Tedeschi PM, Markert EK, Gounder M, Lin H, Dvorzhinski D, Dolfi SC, Chan LL, Qiu J, DiPaola RS, Hirshfield KM, Boros LG, Bertino JR, Oltvai ZN, Vazquez A.

Cell Death Dis. 2013 Oct 24;4:e877. doi: 10.1038/cddis.2013.393.

22.

p63 regulates glutaminase 2 expression.

Giacobbe A, Bongiorno-Borbone L, Bernassola F, Terrinoni A, Markert EK, Levine AJ, Feng Z, Agostini M, Zolla L, Agrò AF, Notterman DA, Melino G, Peschiaroli A.

Cell Cycle. 2013 May 1;12(9):1395-405. doi: 10.4161/cc.24478. Epub 2013 Apr 10.

23.

Molecular profiles of pre- and postoperative breast cancer tumours reveal differentially expressed genes.

Riis ML, Lüders T, Markert EK, Haakensen VD, Nesbakken AJ, Kristensen VN, Bukholm IR.

ISRN Oncol. 2012;2012:450267. doi: 10.5402/2012/450267. Epub 2012 Nov 26.

24.

Proliferation and tissue remodeling in cancer: the hallmarks revisited.

Markert EK, Levine AJ, Vazquez A.

Cell Death Dis. 2012 Oct 4;3:e397. doi: 10.1038/cddis.2012.140.

25.

Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer.

Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, Vousden KH, Muller PA, Dötsch V, Kehrloesser S, Sayan BS, Giaccone G, Lowe SW, Takahashi N, Vandenabeele P, Knight RA, Levine AJ, Melino G.

Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15312-7. Epub 2012 Sep 4. Erratum in: Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2855.

26.

[An uncommon cause of iron deficiency anemia].

Regli M, Meyenberger C, Markert E, Sawatzki M.

Praxis (Bern 1994). 2012 May 23;101(11):735-8. doi: 10.1024/1661-8157/a000947. German.

PMID:
22618698
27.

miR-143 regulates hexokinase 2 expression in cancer cells.

Peschiaroli A, Giacobbe A, Formosa A, Markert EK, Bongiorno-Borbone L, Levine AJ, Candi E, D'Alessandro A, Zolla L, Finazzi Agrò A, Melino G.

Oncogene. 2013 Feb 7;32(6):797-802. doi: 10.1038/onc.2012.100. Epub 2012 Apr 2.

PMID:
22469988
28.

DNA methylation silences miR-132 in prostate cancer.

Formosa A, Lena AM, Markert EK, Cortelli S, Miano R, Mauriello A, Croce N, Vandesompele J, Mestdagh P, Finazzi-Agrò E, Levine AJ, Melino G, Bernardini S, Candi E.

Oncogene. 2013 Jan 3;32(1):127-34. doi: 10.1038/onc.2012.14. Epub 2012 Feb 6.

PMID:
22310291
29.

Molecular classification of prostate cancer using curated expression signatures.

Markert EK, Mizuno H, Vazquez A, Levine AJ.

Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21276-81. doi: 10.1073/pnas.1117029108. Epub 2011 Nov 28.

30.

Serine biosynthesis with one carbon catabolism and the glycine cleavage system represents a novel pathway for ATP generation.

Vazquez A, Markert EK, Oltvai ZN.

PLoS One. 2011;6(11):e25881. doi: 10.1371/journal.pone.0025881. Epub 2011 Nov 2.

31.

Benchmarking of mutation diagnostics in clinical lung cancer specimens.

Querings S, Altmüller J, Ansén S, Zander T, Seidel D, Gabler F, Peifer M, Markert E, Stemshorn K, Timmermann B, Saal B, Klose S, Ernestus K, Scheffler M, Engel-Riedel W, Stoelben E, Brambilla E, Wolf J, Nürnberg P, Thomas RK.

PLoS One. 2011 May 5;6(5):e19601. doi: 10.1371/journal.pone.0019601.

32.

The origins and evolution of the p53 family of genes.

Belyi VA, Ak P, Markert E, Wang H, Hu W, Puzio-Kuter A, Levine AJ.

Cold Spring Harb Perspect Biol. 2010 Jun;2(6):a001198. doi: 10.1101/cshperspect.a001198. Epub 2009 Dec 16. Review.

33.

Higher order Boolean networks as models of cell state dynamics.

Markert EK, Baas N, Levine AJ, Vazquez A.

J Theor Biol. 2010 Jun 7;264(3):945-51. doi: 10.1016/j.jtbi.2010.03.015. Epub 2010 Mar 18.

PMID:
20303985
34.

Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors.

Ansén S, Bangard C, Querings S, Gabler F, Scheffler M, Seidel D, Saal B, Zander T, Nogová L, Töpelt K, Markert E, Stoelben E, Ernestus K, Thomas RK, Wolf J.

J Thorac Oncol. 2010 Mar;5(3):407-9. doi: 10.1097/JTO.0b013e3181cf32aa. No abstract available. Erratum in: J Thorac Oncol. 2010 Jun;5(6):926.

35.

Improving the efficacy of targeted trials by multiple-marker analysis in castration-resistant prostate cancer.

Ohlmann CH, Markert E, Gerharz M, Dienes HP, Stöckle M, Engelmann U, Heidenreich A.

Urol Oncol. 2011 Nov-Dec;29(6):664-9. doi: 10.1016/j.urolonc.2009.09.010. Epub 2009 Nov 26.

PMID:
19942459
36.

High diagnostic value of morphologic examination and molecular analysis of bone marrow biopsies in a case of BCR-ABL+ CML with clusters of blasts.

Markert E, Siebolts U, Odenthal M, Kreuzer KA, Wickenhauser C.

Int J Hematol. 2009 Apr;89(3):294-297. doi: 10.1007/s12185-009-0257-x. Epub 2009 Feb 20.

PMID:
19229589
37.

Evolution of PTLD following renal transplantation in a child.

Markert E, Siebolts U, Habbig S, Odenthal M, Dienes HP, Stippel DL, Hoppe B, Wickenhauser C.

Pediatr Transplant. 2009 May;13(3):379-83. doi: 10.1111/j.1399-3046.2008.00988.x. Epub 2008 Oct 7.

PMID:
19017284
38.

[Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer].

Ohlmann CH, Markert E, Gerharz M, Pfister D, Dienes HP, Engelmann U, Heidenreich A.

Urologe A. 2008 Sep;47(9):1218-23. doi: 10.1007/s00120-008-1839-6. German.

PMID:
18679646
39.

[Dysphagia as a presenting symptom of a cervical neurofibroma].

Vent J, Quante G, Markert E, Klussmann JP, Beutner D.

HNO. 2009 Jun;57(6):625-8. doi: 10.1007/s00106-008-1786-y. German.

PMID:
18587543
40.

Enhanced proliferation and decreased apoptosis in lung lavage cells of sarcoidosis patients.

Petzmann S, Maercker C, Markert E, Kern I, Osolnik K, Pohl W, Popper HH.

Sarcoidosis Vasc Diffuse Lung Dis. 2006 Oct;23(3):190-200.

PMID:
18038918
41.

Lung osteoma--a new benign lung lesion.

Markert E, Gruber-Moesenbacher U, Porubsky C, Popper HH.

Virchows Arch. 2006 Jul;449(1):117-20. Epub 2006 Apr 26.

PMID:
16639606
42.

Association of (Q)R/KRAA positive HLA-DRB1 alleles with disease progression in early active and severe rheumatoid arthritis.

Seidl C, Koch U, Buhleier T, Möller B, Wigand R, Markert E, Koller-Wagner G, Seifried E, Kaltwasser JP.

J Rheumatol. 1999 Apr;26(4):773-6.

PMID:
10229395
43.

Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: comparison of low-dose cyclosporin and parenteral gold.

Zeidler HK, Kvien TK, Hannonen P, Wollheim FA, Førre O, Geidel H, Hafström I, Kaltwasser JP, Leirisalo-Repo M, Manger B, Laasonen L, Markert ER, Prestele H, Kurki P.

Br J Rheumatol. 1998 Aug;37(8):874-82.

PMID:
9734679
44.

HLA-DR/DQ/DP interactions in rheumatoid arthritis.

Seidl C, Koch U, Brünnler G, Buhleier T, Frank R, Möller B, Markert E, Koller-Wagner G, Seifried E, Kaltwasser JP.

Eur J Immunogenet. 1997 Oct;24(5):365-76.

PMID:
9442804
45.

HLA-DRB1*04 subtypes are associated with increased inflammatory activity in early rheumatoid arthritis.

Seidl C, Koch U, Buhleier T, Frank R, Möller B, Markert E, Koller-Wagner G, Seifried E, Kaltwasser JP.

Br J Rheumatol. 1997 Sep;36(9):941-4.

PMID:
9376988
46.

Diclofenac combined with cyclosporine in treatment refractory rheumatoid arthritis: longitudinal safety assessment and evidence of a pharmacokinetic/dynamic interaction.

Kovarik JM, Kurki P, Mueller E, Guerret M, Markert E, Alten R, Zeidler H, Genth-Stolzenburg S.

J Rheumatol. 1996 Dec;23(12):2033-8.

PMID:
8970037
47.

[Research on the Gma frequency in the Liepzig area].

HUNGER H, MARKERT E.

Dtsch Gesundheitsw. 1961 Jul 6;16:1253-4. German. No abstract available.

PMID:
13716828

Supplemental Content

Loading ...
Support Center